118 related articles for article (PubMed ID: 38824626)
1. Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.
Schein J; Cloutier M; Gauthier-Loiselle M; Catillon M; Xu C; Chan D; Childress A
J Manag Care Spec Pharm; 2024 Jun; 30(6):528-540. PubMed ID: 38824626
[TBL] [Abstract][Full Text] [Related]
2. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
[TBL] [Abstract][Full Text] [Related]
3. Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder.
Price MZ; Price RL
CNS Drugs; 2023 Jul; 37(7):655-660. PubMed ID: 37430151
[TBL] [Abstract][Full Text] [Related]
4. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
[TBL] [Abstract][Full Text] [Related]
5. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
Najib J; Didenko E; Meleshkina D; Yusupov K; Maw K; Ramnarain J; Tabassum M
Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
Sikirica V; Findling RL; Signorovitch J; Erder MH; Dammerman R; Hodgkins P; Lu M; Xie J; Wu EQ
CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults.
Faison SL; Fry N; Adewole T; Odebo O; Wang Z; Maletic V; Nasser A
J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):155-162. PubMed ID: 33587403
[TBL] [Abstract][Full Text] [Related]
10. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
[TBL] [Abstract][Full Text] [Related]
11. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
[TBL] [Abstract][Full Text] [Related]
12. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
[TBL] [Abstract][Full Text] [Related]
13. Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents.
Raible H; D'Souza MS
Ann Pharmacother; 2023 Dec; 57(12):1436-1448. PubMed ID: 37021356
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
Babcock T; Dirks B; Adeyi B; Scheckner B
BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
Dittmann RW; Cardo E; Nagy P; Anderson CS; Bloomfield R; Caballero B; Higgins N; Hodgkins P; Lyne A; Civil R; Coghill D
CNS Drugs; 2013 Dec; 27(12):1081-92. PubMed ID: 23959815
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A
CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Stuhec M; Munda B; Svab V; Locatelli I
J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
[TBL] [Abstract][Full Text] [Related]
18. Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity Disorder.
Shafrin J; Shrestha A; Chandra A; Erder MH; Sikirica V
Health Econ; 2017 Nov; 26(11):1459-1466. PubMed ID: 27620206
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials.
Adler LA; Adams J; Madera-McDonough J; Kohegyi E; Hobart M; Chang D; Angelicola M; McQuade R; Liebowitz M
J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5):429-439. PubMed ID: 35652746
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA
PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]